Theratechnologies Inc (TSE:TH) hit a new 52-week low on Tuesday . The company traded as low as C$4.86 and last traded at C$5.56, with a volume of 97732 shares trading hands. The stock had previously closed at C$5.42.
A number of equities research analysts have weighed in on the company. Mackie reduced their price objective on Theratechnologies from C$8.15 to C$7.00 and set a “hold” rating for the company in a research note on Friday, July 12th. National Bank Financial reduced their price objective on Theratechnologies from C$11.25 to C$8.25 and set a “sector perform” rating for the company in a research note on Friday, July 12th. Royal Bank of Canada reduced their price objective on Theratechnologies from C$10.00 to C$8.00 in a research note on Wednesday, July 3rd. Finally, Stifel Nicolaus assumed coverage on Theratechnologies in a research note on Tuesday, May 14th. They issued a “buy” rating and a C$15.00 price objective for the company. Two analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Theratechnologies has a consensus rating of “Buy” and an average target price of C$9.56.
The company has a market capitalization of $417.09 million and a price-to-earnings ratio of -92.70. The company has a debt-to-equity ratio of 159.35, a quick ratio of 2.09 and a current ratio of 2.69. The firm’s fifty day moving average is C$6.23.
Several large investors have recently added to or reduced their stakes in the company. Virtu Financial LLC acquired a new position in shares of Theratechnologies in the first quarter valued at approximately $96,000. Mesirow Financial Investment Management Inc. acquired a new position in Theratechnologies during the first quarter worth $328,000. LLBH Private Wealth Management LLC acquired a new position in Theratechnologies during the first quarter worth $1,735,000. Finally, Monarch Partners Asset Management LLC acquired a new position in Theratechnologies during the first quarter worth $4,256,000.
Theratechnologies Company Profile (TSE:TH)
Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States.
Recommended Story: How is inflation measured?
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.